Crossmark

Clinical utility of polyethylene glycol conjugated granulocyte colony-stimulating factor (PEG-G-CSF) for preventing severe neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI plus bevacizumab: a single-center retrospective study

Crossref DOI link: https://doi.org/10.1186/s12885-020-06864-8

Published Online: 2020-04-28

Published Print: 2020-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Kitagawa, Yusuke

Osumi, Hiroki

Shinozaki, Eiji

Ota, Yumiko

Nakayama, Izuma

Suzuki, Takeshi

Wakatsuki, Takeru

Ogura, Mariko

Ooki, Akira

Takahari, Daisuke

Suenaga, Mitsukuni

Chin, Keisho

Yamaguchi, Kensei
License Information

Text and Data Mining valid from 2020-04-28

Version of Record valid from 2020-04-28
More Information

Article History

Received: 3 September 2019

Accepted: 14 April 2020

First Online: 28 April 2020

Ethics approval and consent to participate

: The study was performed in accordance with the Declaration of Helsinki and was approved by the Cancer Institute Hospital Institutional Review Board (Registry no: 2018–1014). The protocol summary was described on the hospital website, and the subjects were provided with the opportunity to opt-out. Therefore, no new consent for this study was required from the patients.

: Not applicable.

: The author reports no conflicts of interest in this work.

Document is current

Any future updates will be listed below